Plain-English translation of NCT04662294 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing CD70 CAR T, a new type of immune cell therapy designed to fight certain blood cancers. Researchers will give patients their own immune cells that have been specially trained in a lab to recognize and attack cancer cells marked with CD70. The main goal is to understand how safe this treatment is and how well it works for people with acute myeloid leukemia, non-Hodgkin's lymphoma, or multiple myeloma that hasn't responded to standard treatments.
Many patients with these blood cancers stop responding to standard chemotherapy, leaving them with few good options. This trial exists to see whether this new immune-based approach can help patients whose cancers are resistant to conventional treatment.
You likely qualify if…
You likely don't qualify if…
If you qualify, doctors will remove some of your blood cells and send them to a lab where they will be genetically modified to recognize and attack your cancer. While your cells are being prepared—a process that takes several weeks—you may receive additional treatments. Once your modified cells are ready, they will be returned to your body through an infusion. You will then be monitored closely with regular blood tests, imaging scans, and clinic visits to track how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Zhejiang University
Collaborators
Yake Biotechnology Ltd.
Enrollment target
~108 participants
Started
November 2021
Primary completion
January 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in November 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
He Huang, PhD
Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.